Charles David Blanke
Impact in
- Gastroenterology top 0.01%
- Gastrointestinal Tumor Research and Treatment
- Oncology top 0.2%
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
Papers in
-
- Gastrointestinal Tumor Research and Treatment 49
- Oncology 80
- Colorectal Cancer Treatments and Studies 42
- Cancer Treatment and Pharmacology 11
- Co-authors
- Margaret von Mehren (18 shared papers)George D. Demetri (16 shared papers)Michael Charles Heinrich (21 shared papers)Christopher L. Corless (19 shared papers)Christopher D.�M. Fletcher (10 shared papers)Burton Larry Eisenberg (11 shared papers)Heikki Joensuu (7 shared papers)Jonathan Alfred Fletcher (4 shared papers)
- Journals
- Journal of Clinical Oncology (38 papers)Annals of Oncology (17 papers)Clinical Cancer Research (13 papers)Cancer (12 papers)JAMA Oncology (11 papers)
- Partner nations
- United StatesCanadaSwitzerland
In The Last Decade
Charles David Blanke
233 papers receiving 23.9k citations
Charles David Blanke's Hit Papers
Peers
Comparison fields: 5 of 144
- Gastroenterology 9.0k
- Oncology 7.9k
- Pulmonary and Respiratory Medicine 8.6k
- Hepatology 1.1k
- Hematology 1.4k
Countries citing papers authored by Charles David Blanke
This map shows the geographic impact of Charles David Blanke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles David Blanke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles David Blanke more than expected).
Fields of papers citing papers by Charles David Blanke
This network shows the impact of papers produced by Charles David Blanke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles David Blanke. The network helps show where Charles David Blanke may publish in the future.
Co-authors
The 25 scholars most cited alongside Charles David Blanke, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 238 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors Hit paper breakdown → | 2002 | 3642 |
| 2 | Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer Hit paper breakdown → | 2000 | 2540 |
| 3 | Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor Hit paper breakdown → | 2003 | 1922 |
| 4 | Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2009 | 1080 |
| 5 | Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033 Hit paper breakdown → | 2008 | 861 |
| 6 | Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT Hit paper breakdown → | 2008 | 836 |
| 7 | Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer Hit paper breakdown → | 2017 | 711 |
| 8 | Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors Hit paper breakdown → | 2006 | 678 |
| 9 | Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection Hit paper breakdown → | 2012 | 657 |
| 10 | 2005 | 597 | |
| 11 | Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205 Hit paper breakdown → | 2010 | 541 |
| 12 | NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines Hit paper breakdown → | 2007 | 503 |
| 13 | Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group Hit paper breakdown → | 2008 | 492 |
| 14 | 2008 | 326 | |
| 15 | 2009 | 320 | |
| 16 | 2002 | 304 | |
| 17 | SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma Hit paper breakdown → | 2015 | 285 |
| 18 | 2006 | 269 | |
| 19 | A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors Hit paper breakdown → | 2020 | 266 |
| 20 | Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome Hit paper breakdown → | 2019 | 251 |
About Charles David Blanke
Charles David Blanke is a scholar working on Gastroenterology, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Surgery, having authored 238 papers that have together received 24.9k indexed citations. Recurring topics across this work include Gastrointestinal Tumor Research and Treatment (49 papers), Colorectal Cancer Treatments and Studies (42 papers), Gastric Cancer Management and Outcomes (35 papers), Cancer Treatment and Pharmacology (11 papers), Lung Cancer Treatments and Mutations (11 papers), Cancer Genomics and Diagnostics (11 papers), Genetic factors in colorectal cancer (11 papers) and Esophageal Cancer Research and Treatment (11 papers). The work is most often cited by research in Gastroenterology (9.0k citations), Oncology (7.9k citations), Pulmonary and Respiratory Medicine (8.6k citations), Hepatology (1.1k citations) and Hematology (1.4k citations). Charles David Blanke has collaborated with scholars based in United States, Canada and Switzerland. Frequent co-authors include Margaret von Mehren, George D. Demetri, Michael Charles Heinrich, Christopher L. Corless, Christopher D.�M. Fletcher, Burton Larry Eisenberg, Heikki Joensuu, Jonathan Alfred Fletcher, Leonard B. Saltz and Peter James Joseph Roberts. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, Cancer and JAMA Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.